Department of Emergency Medicine and Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.
General Therapeutics, US Medical Affairs, Sanofi US, Bridgewater, NJ.
J Allergy Clin Immunol Pract. 2013 May-Jun;1(3):266-72.e1-3. doi: 10.1016/j.jaip.2013.02.004. Epub 2013 Apr 9.
Auvi-Q is a novel epinephrine autoinjector (EAI) that provides audio and visual cues for patients at risk for life-threatening allergic reactions.
We tested the preference for Auvi-Q or EpiPen with regard to method of instruction, preference to carry, device size, and device shape.
This large, multicenter, simulated-use study evaluated whether adults (aged 18-65 years), caregivers (parents/guardians aged 18-65 years of children aged 5-17 years), and children (aged 11-17 years), with and without experience in using an EAI, had a preference for the current design of Auvi-Q or the current design of EpiPen. Participants were given a scenario that involved anaphylaxis and were instructed to simulate use of an EAI. They received and tested each device individually according to the randomization assignment. After testing both devices, they completed a survey to indicate their preference for Auvi-Q versus EpiPen.
Among all 693 participants combined, Auvi-Q was preferred over EpiPen on all study end points (P < .001). For experienced and inexperienced participants in all 3 groups (adults, caregivers, and children), Auvi-Q was preferred over EpiPen for method of instruction, preference to carry, and device size (all P < .001). The preference for Auvi-Q device shape was not significant among experienced children (P = .10); however, it was significant for inexperienced children (P = .04) and highly significant for experienced and inexperienced adults and caregivers (P < .001).
In this large multicenter, simulated-use study, Auvi-Q was preferred over EpiPen by experienced and inexperienced adults, caregivers, and children.
Auvi-Q 是一种新型肾上腺素自动注射器（EAI），可为有发生危及生命的过敏反应风险的患者提供音频和视觉提示。
我们测试了 Auvi-Q 或 EpiPen 在以下方面的偏好：指示方法、携带偏好、设备尺寸和设备形状。
这项大型的、多中心的模拟使用研究评估了成年人（18-65 岁）、有 5-17 岁儿童的父母/监护人（18-65 岁）和 11-17 岁的儿童（有或没有使用 EAI 的经验）是否对 Auvi-Q 的当前设计或 EpiPen 的当前设计有偏好。参与者接受了涉及过敏反应的情景模拟，并按照随机分组进行 EAI 模拟使用的指导。他们单独接受并测试了每个设备，然后完成了一项调查，以表明他们对 Auvi-Q 与 EpiPen 的偏好。
在所有 693 名参与者中，Auvi-Q 在所有研究终点（P <.001）上均优于 EpiPen。对于所有 3 组（成人、护理人员和儿童）的有经验和无经验的参与者，Auvi-Q 在指示方法、携带偏好和设备尺寸方面（所有 P <.001）都优于 EpiPen。有经验的儿童对 Auvi-Q 设备形状的偏好不显著（P =.10）；然而，无经验的儿童对其偏好显著（P =.04），而有经验和无经验的成年人和护理人员的偏好则高度显著（P <.001）。
在这项大型的多中心模拟使用研究中，Auvi-Q 优于 EpiPen，受到有经验和无经验的成年人、护理人员和儿童的青睐。
